Ulrich Lücking
NBE Therapeutics (Switzerland)(CH)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Advanced Breast Cancer Therapies, Cancer Mechanisms and Therapy, Synthesis and Catalytic Reactions, Click Chemistry and Applications
Most-Cited Works
- → Sulfoximines: A Neglected Opportunity in Medicinal Chemistry(2013)639 cited
- → Neglected sulfur(vi) pharmacophores in drug discovery: exploration of novel chemical space by the interplay of drug design and method development(2019)332 cited
- → Tuning glycoside reactivity: New tool for efficient oligosaccharide synthesis(1998)272 cited
- → Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates(2017)204 cited
- → The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models(2019)203 cited
- → Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer(2017)178 cited
- → The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R,2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer(2013)174 cited
- → BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application(2012)155 cited
- → Sulfoximine: Eine vernachlässigte Chance in der medizinischen Chemie(2013)129 cited
- → Synthesis of Highly Enantioenriched Sulfonimidoyl Fluorides and Sulfonimidamides by Stereospecific Sulfur–Fluorine Exchange (SuFEx) Reaction(2020)129 cited